Your browser doesn't support javascript.
loading
Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations.
Ohara, Minami; Suzuki, Yasuhiko; Shinohara, Saki; Gong, Inna Y; Schmerk, Crystal L; Tirona, Rommel G; Schwarz, Ute I; Wen, Ming-Shien; Lee, Ming Ta Michael; Mihara, Kiyoshi; Nutescu, Edith A; Perera, Minoli A; Cavallari, Larisa H; Kim, Richard B; Takahashi, Harumi.
Affiliation
  • Ohara M; Department of Biopharmaceutics, Meiji Pharmaceutical University, Noshio 2-522-1, Kiyose, Tokyo, 204-8588, Japan.
  • Suzuki Y; Department of Biopharmaceutics, Meiji Pharmaceutical University, Noshio 2-522-1, Kiyose, Tokyo, 204-8588, Japan.
  • Shinohara S; Department of Biopharmaceutics, Meiji Pharmaceutical University, Noshio 2-522-1, Kiyose, Tokyo, 204-8588, Japan.
  • Gong IY; Division of Clinical Pharmacology, University of Western Ontario, London, ON, Canada.
  • Schmerk CL; Division of Clinical Pharmacology, University of Western Ontario, London, ON, Canada.
  • Tirona RG; Division of Clinical Pharmacology, University of Western Ontario, London, ON, Canada.
  • Schwarz UI; Division of Clinical Pharmacology, University of Western Ontario, London, ON, Canada.
  • Wen MS; Department of Internal Medicine, Linkou and Chang Gung University College of Medicine, Tauyuan, Taiwan.
  • Lee MTM; Genomic Medicine Institute, Geisinger Health System, Danville, PA, USA.
  • Mihara K; Faculty of Pharmacy, Center for Clinical Pharmacy, Musashino University, Tokyo, Japan.
  • Nutescu EA; Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA.
  • Perera MA; Department of Pharmacology, Northwestern University, Chicago, IL, USA.
  • Cavallari LH; Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA.
  • Kim RB; Division of Clinical Pharmacology, University of Western Ontario, London, ON, Canada.
  • Takahashi H; Department of Biopharmaceutics, Meiji Pharmaceutical University, Noshio 2-522-1, Kiyose, Tokyo, 204-8588, Japan. harumit@my-pharm.ac.jp.
Clin Pharmacokinet ; 58(8): 1077-1089, 2019 08.
Article de En | MEDLINE | ID: mdl-30815847
ABSTRACT

BACKGROUND:

Population differences in warfarin dosing requirement have been reported; however, unlike the pharmacokinetics (PK) of warfarin, the quantitative influences of pharmacodynamic (PD) factors on the anticoagulation response to warfarin in different ethnic populations are totally unknown.

METHODS:

Using population PK/PD analysis, we attempted to identify predictors of S-warfarin clearance [CL(S)] and half maximal effective concentration (EC50) to quantify racial differences in both PK and PD parameters, and to assess the contribution of these parameters to the international normalized ratio (INR) and over-anticoagulation response (INR ≥ 4) in a cohort of 309 White, Asian and African American patients.

RESULTS:

Similar to our previous findings, the median CL(S) was 30% lower in African American patients than Asian and White patients (169 vs. 243 and 234 mL/h, p < 0.01). EC50 showed a greater racial difference than CL(S) [1.03, 1.70 and 2.76 µg/mL for Asian, White and African American patients, respectively, p < 0.01). Significant predictors of INR included demographic/clinical (age, body weight, creatinine clearance and sex) and genotypic (CYP2C9*3,*8 and VKORC1 -1639G>A) factors, as well as African American ethnicity. In all three racial groups, genetic predictors of INR appeared to have greater influence than demographic/clinical predictors. Both CL(S) and EC50 contributed to the over-anticoagulation response to warfarin. Patients having VKORC1 -1639 G>A and/or factors associated with reduced CYP2C9 activity were more likely to have an INR ≥ 4.

CONCLUSIONS:

Although there were contrasting racial differences in CL(S) and EC50 that impacted on the INR, the racial difference in EC50 was greater than that for CL(S), thus explaining the higher warfarin requirement for African American patients.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Warfarine / Rapport international normalisé / Vitamin K epoxide reductases / Cytochrome P-450 CYP2C9 / Anticoagulants Type d'étude: Diagnostic_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Clin Pharmacokinet Année: 2019 Type de document: Article Pays d'affiliation: Japon

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Warfarine / Rapport international normalisé / Vitamin K epoxide reductases / Cytochrome P-450 CYP2C9 / Anticoagulants Type d'étude: Diagnostic_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Clin Pharmacokinet Année: 2019 Type de document: Article Pays d'affiliation: Japon